Altus Pharmaceuticals Hires Dr. Burkhard Blank as Senior Vice President of Medicine, Regulatory Affairs and Project Management.CAMBRIDGE, Mass. -- Altus Pharmaceuticals Inc. (Nasdaq: ALTU), a biopharmaceutical company developing and commercializing oral and injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. protein therapeutics for patients with gastrointestinal and metabolic disorders Noun 1. metabolic disorder - a disorder or defect of metabolism disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder"; "everyone gets stomach upsets from time to time" , announced today that Burkhard Blank, M.D. has been appointed Senior Vice President Medicine, Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: "I am very pleased that Burkhard brings to Altus his extensive expertise in international project management, clinical development, and regulatory affairs," said Sheldon Berkle, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Altus. "In his previous position as Senior Vice President for Medicine and Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals USA, Burkhard successfully managed the many components of an extensive clinical research program. This will be vital to Altus as we work to advance our two lead programs, ALTU-135 and ALTU-238, which we expect to enter pivotal Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the in the second half of this year." While at Boehringer Ingelheim USA, Dr. Blank was responsible for a staff of 600 and an annual recruitment of 8,000-10,000 patients in the North and South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. region. Prior to his position in the USA, he held a number of positions with increasing levels of responsibility at Boehringer's head office in Ingelheim, Germany, the most recent as Head of Division International Project Management and Drug Regulatory Affairs (DRA DRA Delta Regional Authority DRA Developmental Reading Assessment (educational test) DRA Division of Ratepayer Advocates (California) DRA Data Research Associates DRA Directory and Resource Administrator ). In this capacity, he founded the International Project Management Department, which had worldwide responsibility for the planning and monitoring of all Phase I-IV development projects and for all international regulatory submissions. Dr. Blank was also a member of Boehringer's International Development Committee, which was responsible for steering their global drug development portfolio. He holds a medical degree in internal medicine from Universitaet Marburg, Germany. About Altus Pharmaceuticals Inc.: Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion